References
- Bennett C L, Armitahe J L, Buchner D, Gulati S. Economic analysis in phase III clinical trials. Cancer Invest 1996; 12: 336–342
- Gold M R, Siegel J E, Russell L B, Weinstein M D. Cost-Effectiveness in Health and Medicine. Oxford University Press, New York 1996
- Hsiao W C, Couch N P, Causino N. Resource-based relative values for invasive procedures performed by eight surgical specialties. JAMA 1988; 260: 2418–2424
- Weinstein M C, Siegel J E, Gold M R. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1253–1258
- Taplin S H, Barlow W, Urban N. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995; 87: 417–426
- Riley G F, Potosky A L, Lubitz J D, Kessler L G. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995; 33: 828–841
- Tuck J, Walker A, Whynes D K. Screening and the costs of treating colorectal cancer: some preliminary results. Public Health 1989; 103: 413–419
- Rozen P, Ron E. A cost analysis of screening methodology for family members of colorectal cancer patients. Am J Gastroenterol 1989; 84: 1548–1551